{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T18:31:32Z","timestamp":1675017092037},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00105-019-4390-z","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T08:05:20Z","timestamp":1552550720000},"page":"236-242","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapie des bull\u00f6sen Pemphigoids"],"prefix":"10.1007","volume":"70","author":[{"given":"M.","family":"G\u00f6bel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Eming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"issue":"11","key":"4390_CR1","first-page":"1339","volume":"16","author":"SC Hofmann","year":"2018","unstructured":"Hofmann SC, Juratli HA, Eming R (2018) Bullous autoimmune dermatoses. J\u00a0Dtsch Dermatol Ges 16(11):1339\u20131360","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"4390_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1610-0387.2008.06976.x","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram F et\u00a0al (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J\u00a0Dtsch Dermatol Ges 7(5):434\u2013440. \n                    https:\/\/doi.org\/10.1111\/j.1610-0387.2008.06976.x","journal-title":"J Dtsch Dermatol Ges"},{"issue":"12","key":"4390_CR3","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","volume":"136","author":"F H\u00fcbner","year":"2016","unstructured":"H\u00fcbner F et\u00a0al (2016) Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J\u00a0Invest Dermatol 136(12):2495\u20132498. \n                    https:\/\/doi.org\/10.1016\/j.jid.2016.07.013","journal-title":"J Invest Dermatol"},{"issue":"1","key":"4390_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00105-015-3723-9","volume":"67","author":"K Hoffmann","year":"2016","unstructured":"Hoffmann K, Hertl M, Sitaru C (2016) Molecular diagnosis of autoimmune dermatoses. Hautarzt 67(1):33\u201339","journal-title":"Hautarzt"},{"key":"4390_CR5","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","volume":"337","author":"SM Langan","year":"2008","unstructured":"Langan SM (2008) Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study. BMJ 337:a180. \n                    https:\/\/doi.org\/10.1136\/bmj.a180","journal-title":"BMJ"},{"key":"4390_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.det.2011.03.010","volume":"29","author":"E Schmidt","year":"2011","unstructured":"Schmidt E, della Torre R, Borradori L (2011) Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 29:427","journal-title":"Dermatol Clin"},{"key":"4390_CR7","doi-asserted-by":"publisher","first-page":"37125","DOI":"10.1038\/srep37125","volume":"6","author":"AK F\u00f6rsti","year":"2016","unstructured":"F\u00f6rsti AK et\u00a0al (2016) Psychiatric and neurological disorders are associated with bullous pemphigoid\u2014a\u00a0nationwide Finnish Care Register study. Sci Rep 6:37125. \n                    https:\/\/doi.org\/10.1038\/srep37125","journal-title":"Sci Rep"},{"issue":"5","key":"4390_CR8","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/jid.2014.547","volume":"135","author":"F Schulze","year":"2015","unstructured":"Schulze F et\u00a0al (2015) Malignancies in pemphigus and pemphigoid diseases. J\u00a0Invest Dermatol 135(5):1445\u20131447. \n                    https:\/\/doi.org\/10.1038\/jid.2014.547","journal-title":"J Invest Dermatol"},{"key":"4390_CR9","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3389\/fimmu.2018.02687","volume":"9","author":"RM Chiorean","year":"2018","unstructured":"Chiorean RM, Baican A, Mustafa MB et al (2018) Complement-activating capacity of autoantibodies correlates with disease activity in bullous pemphigoid patients. Front Immunol 9:2687","journal-title":"Front Immunol"},{"issue":"1","key":"4390_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjd.12308","volume":"169","author":"JB Terra","year":"2013","unstructured":"Terra JB, Meijer JM, Jonkman MF, Diercks GF (2013) The n\u2011 vs. u\u2011serration is a\u00a0learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis. Br J Dermatol 169(1):100\u2013105","journal-title":"Br J Dermatol"},{"key":"4390_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"P Joly","year":"2002","unstructured":"Joly P, Roujeau JC, Benichou J et\u00a0al (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346:321\u2013327","journal-title":"N. Engl. J. Med."},{"issue":"17\u201318","key":"4390_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10354-014-0294-9","volume":"164","author":"A Kneisel","year":"2014","unstructured":"Kneisel A, Hertl M (2014) Bullous pemphigoid: diagnosis and therapy. Wien Med Wochenschr 164(17\u201318):363\u2013371","journal-title":"Wien Med Wochenschr"},{"issue":"4","key":"4390_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","volume":"172","author":"C Feliciani","year":"2015","unstructured":"Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D, Borradori L et\u00a0al (2015) Management of bullous pemphigoid: The European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol 172(4):867\u2013877. \n                    https:\/\/doi.org\/10.1111\/bjd.13717","journal-title":"Br J Dermatol"},{"issue":"8","key":"4390_CR14","first-page":"833","volume":"13","author":"R Eming","year":"2015","unstructured":"Eming R, Sticherling M, Hofmann SC et\u00a0al (2015) S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid. J\u00a0Dtsch Dermatol Ges 13(8):833\u2013844","journal-title":"J Dtsch Dermatol Ges"},{"key":"4390_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","volume":"66","author":"DF Murrell","year":"2012","unstructured":"Murrell DF, Daniel BS, Joly P et\u00a0al (2012) Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J\u00a0Am Acad Dermatol 66:479\u2013485","journal-title":"J Am Acad Dermatol"},{"key":"4390_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.det.2011.06.009","volume":"29","author":"V Meyer","year":"2011","unstructured":"Meyer V, Beissert S (2011) Azathioprine in the treatment of autoimmune blistering diseases. Dermatol Clin 29:545\u2013554","journal-title":"Dermatol Clin"},{"issue":"3","key":"4390_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/1346-8138.14173","volume":"45","author":"R Kakuta","year":"2018","unstructured":"Kakuta R, Yamagami J, Funakoshi T, Takahashi H, Ohyama M, Amagai M (2018) Azathioprine monotherapy in autoimmune blistering diseases: a feasible option for mild to moderate cases. J\u00a0Dermatol 45(3):334\u2013339","journal-title":"J Dermatol"},{"issue":"6","key":"4390_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","volume":"10","author":"HM G\u00fcrcan","year":"2009","unstructured":"G\u00fcrcan HM, Ahmed AR (2009) Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 10(6):383\u2013396","journal-title":"Am J Clin Dermatol"},{"key":"4390_CR19","series-title":"Springer Reference Medizin","volume-title":"Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie","author":"S Schreml","year":"2018","unstructured":"Schreml S, Gollnick H (2018) Systemische Therapie bei Hauterkrankungen. In: Plewig G, Ruzicka T, Kaufmann R, Hertl M (Hrsg) Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie. Springer Reference Medizin. Springer, Berlin, Heidelberg"},{"issue":"5","key":"4390_CR20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/bjd.15649","volume":"177","author":"M Sticherling","year":"2017","unstructured":"Sticherling M et\u00a0al (2017) An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 177(5):1299\u20131305. \n                    https:\/\/doi.org\/10.1111\/bjd.15649","journal-title":"Br J Dermatol"},{"key":"4390_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30560-3","author":"HC Williams","year":"2017","unstructured":"Williams HC, Wojnarowski F, Kirtschig G et al (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a\u00a0pragmatic, non-inferiority, randomised controlled trial. Lancet. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)30560-3","journal-title":"Lancet"},{"key":"4390_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","volume":"130","author":"DP Fivenson","year":"1994","unstructured":"Fivenson DP, Breneman DL, Rosen GB et\u00a0al (1994) Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 130:753\u2013758","journal-title":"Arch Dermatol"},{"issue":"3","key":"4390_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2340\/00015555-1925","volume":"95","author":"L Kibsgaard","year":"2015","unstructured":"Kibsgaard L, Bay B, Deleuran M, Vestergaard C (2015) A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a\u00a0tertiary centre. Acta Derm Venereol 95(3):307\u2013311","journal-title":"Acta Derm Venereol"},{"key":"4390_CR24","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","volume":"143","author":"S Beissert","year":"2007","unstructured":"Beissert S, Werfel T, Frieling U et\u00a0al (2007) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 143:1536\u20131542","journal-title":"Arch Dermatol"},{"issue":"12","key":"4390_CR25","first-page":"1211","volume":"15","author":"JHO Hoffmann","year":"2017","unstructured":"Hoffmann JHO, Enk AH (2017) Hochdosierte intraven\u00f6se Immunglobuline bei dermatologischen Autoimmunerkrankungen. J\u00a0Dtsch Dermatol Ges 15(12):1211\u20131227","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"2","key":"4390_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","volume":"85","author":"M Amagai","year":"2017","unstructured":"Amagai M, Ikeda S, Hashimoto T, Mizuashi M et al (2017) A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J\u00a0Dermatol Sci 85(2):77\u201384","journal-title":"J Dermatol Sci"},{"issue":"6","key":"4390_CR27","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1067\/mjd.2001.116337","volume":"45","author":"AR Ahmed","year":"2001","unstructured":"Ahmed AR (2001) Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J\u00a0Am Acad Dermatol 45(6):825\u2013835","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"4390_CR28","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/ddg.13642_g","volume":"16","author":"F H\u00fcbner","year":"2018","unstructured":"H\u00fcbner F et al (2018) Adjuvante Behandlung des schweren\/refrakt\u00e4ren bull\u00f6sen Pemphigoids mit Protein-A-Immunadsorption. J\u00a0Dtsch Dermatol Ges 16(9):1109\u20131119. \n                    https:\/\/doi.org\/10.1111\/ddg.13642_g","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"4390_CR29","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jaad.2014.06.014","volume":"71","author":"M Kasperkiewicz","year":"2014","unstructured":"Kasperkiewicz M, Schulze F, Meier M, van Beek N, Nitschke M, Zillikens D, Schmidt E (2014) Treatment of bullous pemphigoid with adjuvant immunoadsorption: a\u00a0case series. J\u00a0Am Acad Dermatol 71(5):1018\u20131020","journal-title":"J Am Acad Dermatol"},{"key":"4390_CR30","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14474.1","author":"J Yamagami","year":"2018","unstructured":"Yamagami J (2018) Recent advances in the understanding and treatment of pemphigus and pemphigoid. Version 1; referees: 2 approved. F1000 Fac Rev. \n                    https:\/\/doi.org\/10.12688\/f1000research.14474.1","journal-title":"F1000 Fac Rev"},{"issue":"3","key":"4390_CR31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","volume":"65","author":"M Kasperkiewicz","year":"2011","unstructured":"Kasperkiewicz M et al (2011) Rituximab for treatment-refractory pemphigus and pemphigoid: a\u00a0case series of 17 patients. J\u00a0Am Acad Dermatol 65(3):552\u2013558. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2010.07.032","journal-title":"J Am Acad Dermatol"},{"key":"4390_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","volume":"9","author":"A Lamberts","year":"2018","unstructured":"Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horv\u00e1th B (2018) Effectiveness and safety of Rituximab in recalcitrant pemphigoid diseases. Front Immunol 9:248","journal-title":"Front Immunol"},{"issue":"1","key":"4390_CR33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjd.13633","volume":"173","author":"YT Cho","year":"2015","unstructured":"Cho YT, Chu CY, Wang LF (2015) First-line combination therapy with rituximab and corticosteroids provides a\u00a0high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol 173(1):302\u2013304","journal-title":"Br J Dermatol"},{"issue":"15","key":"4390_CR34","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","volume":"78","author":"KT Amber","year":"2018","unstructured":"Amber KT, Maglie R, Solimani F, Eming R, Hertl M (2018) Targeted therapies for autoimmune bullous diseases: current status. Drugs 78(15):1527\u20131548","journal-title":"Drugs"},{"key":"4390_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coph.2018.12.007","volume":"46","author":"R Maglie","year":"2019","unstructured":"Maglie R, Hertl M (2019) Pharmacological advances in pemphigoid. Curr Opin Pharmacol 46:34\u201343","journal-title":"Curr Opin Pharmacol"},{"key":"4390_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","volume":"153","author":"N Beek Van","year":"2017","unstructured":"Van Beek N, L\u00fcttmann N, Huebner F, Recke A, Karl I, Schulze FS et\u00a0al (2017) Correlation of serum levels of ige autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol 153:30\u201338","journal-title":"JAMA Dermatol."},{"issue":"3","key":"4390_CR37","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","volume":"71","author":"KK Yu","year":"2014","unstructured":"Yu KK et\u00a0al (2014) Omalizumab therapy for bullous pemphigoid. J\u00a0Am Acad Dermatol 71(3):468\u2013474. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2014.04.053","journal-title":"J Am Acad Dermatol"},{"key":"4390_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","volume":"96","author":"L Chakievska","year":"2019","unstructured":"Chakievska L, Holtsche MM et al (2019) IL-17A is functionally relevant and a\u00a0potential therapeutic target in bullous pemphigoid. J\u00a0Autoimmun 96:104\u2013112. \n                    https:\/\/doi.org\/10.1016\/j.jaut.2018.09.003","journal-title":"J Autoimmun"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-4390-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-019-4390-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-4390-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:29:12Z","timestamp":1554460152000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-019-4390-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["4390"],"URL":"https:\/\/doi.org\/10.1007\/s00105-019-4390-z","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"12 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0G\u00f6bel und R.\u00a0Eming geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. Alle Patienten, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Im Falle von nicht m\u00fcndigen Patienten liegt die Einwilligung eines Erziehungsberechtigten oder des gesetzlich bestellten Betreuers vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}